Wall Street is positive on Evofem Biosciences Inc (EVFM). On average, analysts give Evofem Biosciences Inc a Strong Buy rating. The average price target is $16.492, which means analysts expect the stock to increase by 1516.86% over the next twelve months. That average ranking earns Evofem Biosciences Inc an Analyst Rating of 41, which is better than 41% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating EVFM a Strong Buy today. Find out what this means to you and get the rest of the rankings on EVFM!